Close Menu

NEW YORK (GenomeWeb) – Researchers from Alnylam Pharmaceuticals this week published a study describing the company's development of GalNAc conjugates, which Alnylam is using with all of its newest drug candidates to deliver siRNAs into the liver.

The technology is based on N-acetylgalactosamine ligands, which have a high affinity for the asialoglycoprotein (ASGPR) receptors expressed on the surface of hepatocytes. While the concept of using these ligands for drug delivery in not new, doing so has been a challenge.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Google's Project Nightingale has collected health information on millions of Americans, according to the Wall Street Journal.

An opinion piece at The Hill criticizes the proposed plan to collect DNA samples from migrants at the US border.

Nature News writes that women in chemistry are less likely to have their manuscripts accepted for publication.

In PNAS this week: tRNA fragment signature for chronic lymphocytic leukemia, genomic sites sensitive to ultraviolet radiation in melanocytes, and more.